Blood Tests to Find Early Plasma Cell Disorders in Adults
Checks blood samples for early plasma cell disorders in adults 30 and older.
Plain-language title generated from the registry record
Registry title: CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Key facts
- Where
- Charlotte, United StatesSee the site
Where in United States
- Atrium Health Levine CancerCharlotte, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT06644625
- Record updated
- 13 July 2026
- Original description
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.Read full original descriptionShow less
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
SCREENING Inclusion Criteria:; Age 30 years or older at the time of consent; Either:; Self-identify as Black and/or African American OR; First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia; Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately; Reside in Charlotte, NC, or the surrounding area, based on self-report; SCREENING Exclusion Criteria:; Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS; LONGITUDINAL Inclusion Criteria:; Test positive for monoclonal gammopathy during screening portion of the study; Consent to the longitudinal portion of the study; LONGITUDINAL Exclusion Criteria:; The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.